Sirtex swings to a loss after ‘challenging’ year


Sirtex MedicalShares in Australian cancer treatment developer Sirtex Medical (ASX:SRX) plunged more than 15% yesterday after the company posted a net loss of -A$26.9 million in 2016, compared to a profit of A$54 million the year before.

Sirtex has faced a barrage of obstacles this year, including a number of clinical trials that failed to meet primary endpoints. The company’s full-year results were hit by a slowdown in sales growth of its SIR-Spheres Y-90 radioactive microspheres and by the costs linked to its restructuring efforts.

Get the full story at our sister site, Drug Delivery Business News.

Want to stay on top of MDO content? Subscribe to our e-newsletter.

Speak Your Mind